Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study

Diffuse large B-cell lymphoma (DLBCL), either concurrent with or transformed from follicular lymphoma (FL) is often excluded from clinical trials. Lenalidomide has response rates of 45% in relapsed transformed DLBCL. Herein we present an analysis of MC078E, a phase II clinical trial testing lenalido...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Sanjal H., LaPlant, Betsy, Macon, William R., King, Rebecca L., Wang, Yucai, Inwards, David J., Micallef, Ivana, Johnston, Patrick B., Porrata, Luis F., Ansell, Stephen M., Habermann, Thomas M., Witzig, Thomas E., Nowakowski, Grzegorz S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464592/
https://www.ncbi.nlm.nih.gov/pubmed/34564694
http://dx.doi.org/10.1038/s41408-021-00542-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8464592/
https://www.ncbi.nlm.nih.gov/pubmed/34564694
http://dx.doi.org/10.1038/s41408-021-00542-z

Ejemplares similares